Postvaccinal, corticosteroid-resistant bullous pemphigoid in infancy: treatment with intravenous immunoglobulin.

Abstract

Bullous pemphigoid is an autoimmune subepidermal blistering disorder that typically affects elderly adults but can also occur in childhood. We report on a 3-month-old boy who developed bullous pemphigoid 1 week after the second routine administration of a hexavalent vaccine. The disease was resistant to standard therapies (including oral and topical corticosteroids) but was relieved by intravenous immunoglobulin treatment. There was no recurrence of bullous pemphigoid after the next vaccination (3 mos after discontinuation of steroids).

• Authors: Marielle Ister, Guillaume Pouessel, Hubert Ythier, Benoit Catteau, Olivier Carpentier
• Journal: Pediatric dermatology (Pediatr Dermatol) 2014 Jul-Aug Vol. 31 Issue 4 Pg. e94-5 ISSN: 1525-1470 [Electronic] United States
• PMID: 24916151 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2014 Wiley Periodicals, Inc.

Chemical References

• Diphtheria-Tetanus-Pertussis Vaccine
• Glucocorticoids
• Hepatitis B Vaccines
• Hexavac
• Immunoglobulins, Intravenous
• Poliovirus Vaccine, Inactivated
• Betamethasone
• Prednisolone

Topics

• Betamethasone (therapeutic use)
• Diphtheria-Tetanus-Pertussis Vaccine (adverse effects)
• Drug Resistance
• Drug Therapy, Combination
• Exanthema
• Glucocorticoids (therapeutic use)
• Hepatitis B Vaccines (adverse effects)
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Infant
• Male
• Pemphigoid, Bullous (drug therapy, etiology)
• Poliovirus Vaccine, Inactivated (adverse effects)
• Prednisolone (therapeutic use)